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In 1991, a meta-analysis of seven small-scale trials of
intravenous magnesium in a total of 1266 patients
with suspected acute myocardial infarction indicated
a450% reduction in the risk of death associated with
magnesium (relative risk 0.48, 95% CI 0.26–0.88).1
Yusuf et al. updated this meta-analysis in 19932 to
include LIMIT-2,3 at the time the only adequately
sized trial, with a power of 80% to detect a moderate
to large relative reduction in the risk of death of 33%
associated with magnesium. Based on a total of eight
trials in 3617 patients with a pooled relative risk of
0.59 (95% CI 0.38–0.91), the authors concluded that
‘intravenous magnesium is a safe, effective, widely
practicable and inexpensive intervention that has the
potential of making an important impact on the
management of patients with myocardial infarction’.2
In 1995, ISIS-4 became available,4 a large-scale trial
in 58 050 patients, which had nearly 95% power
to detect a small, but potentially clinically relevant
reduction in the relative risk of death of 10%
associated with magnesium. ISIS-4 clearly refuted
the earlier meta-analyses and showed a trend towards
more deaths in the patients allocated to magnesium,
with the lower limit of the 95% CI excluding any
relevant benefit of the intervention (relative risk 1.05,
95% CI 0.99–1.12).
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The case of magnesium in acute myocardial infarc-
tion cast serious doubts on the trustworthiness of
meta-analyses. Which meta-analyses were conclusive
and which were likely to be refuted by subsequent
large-scale trials? Intrigued by the magnesium exam-
ple, Egger and Davey Smith5 suggested in 1995 that
funnel plots could have been used as a diagnostic
tool, in which estimates of treatment effect obtained
in trials included in the magnesium meta-analyses1,2
were plotted against a measure of sample size or
statistical precision, to detect bias associated with
small trials. In the absence of bias, the plot will
typically resemble a symmetrical inverted funnel with
the results of smaller trials more widely scattered
than those of larger, more precise trials. Publication
bias,6 and poor design, execution and analysis of
small trials7 may result in skewed funnel plots. Visual
inspection of the funnel plot of magnesium trials and
a formal statistical test of its asymmetry indicated
that the funnel plot was clearly asymmetrical before
ISIS-4 became available.5,7
In 1997, Pogue and Yusuf8,9 took a different
approach and suggested that multiple looks in meta-
analyses of randomized trials may be interpreted
similarly to interim looks in a single trial. The prob-
lem of interim looks in a single trial was originally
addressed by Armitage10 and Pocock11 by group
sequential analysis. Lan and DeMets12 extended the
suggested concept with an alpha-spending function to
allow flexible unplanned monitoring in a trial. They
introduced the cumulative z-curve modelled as a
Brownian motion and an alpha-spending function
according to O’Brien and Flemming13 for the con-
struction of monitoring boundaries. If a treatment
effect larger than expected occurs, a trial should be
terminated early when the cumulative z-curve for this
treatment effect crossed the constructed sequential
monitoring boundary. In early stages of a trial when
data are sparse, only very extreme results correspond-
ing to extreme z-values are accepted to indicate
premature termination of a trial. The monitoring
boundaries become less stringent as more data
accumulate and the planned sample size of the trial
is approached. The same principle could be applied to
meta-analyses to determine when a meta-analysis is
conclusive. Only extreme results leading to z-values
that cross highly stringent boundaries should be
accepted if little information was accrued in a meta-
analysis of few, small-scale trials. Boundaries should
become less stringent as more information accu-
mulates.8,9 In a cumulative meta-analysis of 10
magnesium trials, Pogue and Yusuf8 found that the
cumulative z-curve of the meta-analysis did not cross
the specified monitoring boundary for overall mortal-
ity before ISIS-44 and suggested that the meta-
analysis was not conclusive. However, Egger et al.
identified 15 trials of magnesium in myocardial
infarction published before ISIS-4.4 When based on
all 15 trials, rather than the 10 trials selected by
Pogue and Yusuf, the meta-analysis crossed the moni-
toring boundary and became conclusive, although
the results were still contradicted by ISIS-4.14 Pogue
and Yusuf’s approach failed to become widely
adopted.
Recently, Wetterslev et al. coined the term ‘trial
sequential analysis’ for an extension of Pogue and
Yusuf’s approach, which reflects an increase in uncer-
tainty if heterogeneity between trials is present in a
meta-analysis.15 In this issue, two articles by the same
group use trial sequential analysis to determine
whether results of published meta-analyses in neo-
natology16 and across different fields17 are conclusive.
Accounting for the observed heterogeneity between
trials, they find a substantial proportion of published
meta-analyses potentially inconclusive. In both arti-
cles,16,17 the authors point out that trial sequential
analysis does not deal with systematic errors resulting
from the inclusion of flawed trials18 and outcome
reporting19 or publication biases20 and that these
sources of systematic errors should be appropriately
examined using funnel plots21 and analyses stratified
according to methodological characteristics of trials
accompanied by appropriate tests for interaction
between trial characteristic and effect estimates.22
Here, we re-analyse the trials of intravenous
magnesium in acute myocardial infarction to deter-
mine how the different diagnostic measures—funnel
plots, stratified analyses according to methodological
characteristics of trials and heterogeneity-adjusted
trial sequential analysis—contribute to our under-
standing of bias and inconclusive results at four
stages of the meta-analysis: (A) trials available until
1991, before LIMIT-2;3 (B) trials until 1995, before
ISIS-44 became available; (C) all trials until 1995,
including ISIS-4;4 and (D) all trials available to
date.14,24 Figure 1 presents funnel plots of effect sizes
on the horizontal axis against their standard errors on
the vertical axis, displaying asymmetry as regression
lines with 95% confidence bands derived from pre-
dicting the treatment effect from univariable meta-
regression analysis with the standard error as the
explanatory variable.21 Visual inspection of funnel plot
and regression line suggest asymmetry at all four stages
A–D of the meta-analysis, but Egger’s test for funnel
plot asymmetry23 becomes positive only at stage B, after
the inclusion of LIMIT-2,3 the only adequately sized
trial at that time. In subsequent stages, the shape of the
funnel plot remains essentially unchanged and Egger’s
test for asymmetry positive, suggesting bias.
Table 1 presents the results from corresponding
stratified analyses according to concealment of alloca-
tion and sample size. At stage A, stratified analyses
using a fixed- and a random-effects models indicate
no relevant differences between trials with adequate
concealment and the remaining trials, whereas no
adequately sized trials with sample sizes of 2200
patients or more were available. At stage B, after
LIMIT-23 became available, differences become
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apparent between trials with and without conceal-
ment of allocation and between large and small trials,
but pooled effects are statistically significant in all
stratified analyses and interaction tests are positive
only in fixed-effect meta-analyses. With the inclusion
of ISIS-4,4 the between trial heterogeneity becomes
prominent. Therefore, random-effects models attri-
bute considerably more weight to smaller studies than
fixed-effect models and results from fixed- and
random-effects meta-analyses including all trials are
discordant: there is still a clinically relevant mortality
reduction according to the random-effects, but a
clear-cut null result according to the fixed-effect
meta-analysis. Even in the presence of high between-
trial heterogeneity, random- and fixed-effect models
show concordant results if stratified according to
trial size: no effect in adequately sized trials and an
unrealistically large beneficial effect of magnesium on
overall mortality in small trials. Positive tests of
interaction in both random- and fixed-effect analyses
indicate that these differences between adequately
sized and small trials are unlikely to have occurred by
chance alone.
Figure 2 presents results from trial sequential
analysis using fixed-effect meta-analysis (top) and
random-effects meta-analysis (bottom). The dashed
horizontal line represents the monitoring boundaries to
be reached by the z-value of a meta-analysis to indicate
that results are conclusive before the number of 24 899
patients is reached, which is necessary to detect a
relative risk reduction of 15% with 80% power at a two-
sided a of 0.01. The boundary becomes less stringent
with more patients accruing and will converge to a
z-value of 2.58 corresponding to the a-level of 0.01
indicating conclusive results when sufficient numbers
of patients have been accumulated. Neither in random-
effects, nor in fixed-effect meta-analyses, the z-curve
crosses the boundary before ISIS-4 becomes available
and the necessary information size of nearly 25 000
patients is reached, suggesting that the results of both,
random- and fixed-effect meta-analyses were incon-
clusive. After inclusion of ISIS-4,4 however, results are
conflicting: evidence of a null effect according to
the fixed-effect model, but evidence of a benefit of
magnesium according to the random-effects model,
which vanishes only after the analysis is restricted to
trials with adequate sample size (data available on
request).
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Figure 1 Funnel plots. Funnel plots are presented (A)
for trials published until 1991, before LIMIT-2 became
available; (B) until 1995, before ISIS-4 became available;
(C) until 1995, including ISIS-4; and (D) up to 2004. Dotted
lines indicate predicted treatment effects (regression line)
from univariable meta-regression by using standard error as
explanatory variable; dashed lines represent 95% CI.
Regression lines are truncated at standard errors typically
found in adequately sized trials with sufficient power to
detect a moderate to large relative risk reduction of 30–40%
(stages A and B) and at the standard error found in the
largest trial included in the meta-analysis (stages C and D).
P-values are derived from Egger’s test for funnel plot
asymmetry.23
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It is the overall pattern found in funnel plots, stratified
analyses and heterogeneity-adjusted trial sequential
analysis, which provides a clear-cut insight into the
trustworthiness of the different stages of the meta-
analysis of magnesium in acute myocardial infarc-
tion.1,2,14,24 At stage A, formal tests of funnel plot
asymmetry and interaction tests accompanying strati-
fied analyses are still negative due to a lack of power
and some would have concluded that the evidence
accumulated was unbiased and trustworthy. Hetero-
geneity-adjusted trial sequential analysis unequivocally
indicates, however, that the evidence was inconclusive
at this stage. At stage B, trial sequential analysis sug-
gests that the accumulated evidence is still unconvin-
cing even though LIMIT-23 was included. In addition,
the test for funnel plot asymmetry becomes positive.
At stages C and D, after the inclusion of ISIS-4,4
heterogeneity-adjusted trial sequential analyses of
Table 1 Stratified analyses
Random-effects meta-analysisFixed-effect meta-analysis
Number
of trials
Number
of patients
Relative risk
(95% CI)
P-value for
interaction
Relative risk
(95% CI)
P-value for
interaction
Heterogeneity
I2 (%)
A. Until 1991, before LIMIT-214
Overall 13 2028 0.46 (0.32–0.65) 0.42 (0.30–0.59) 0.0
Concealment of allocation 0.99 0.89
Adequate 2 551 0.45 (0.20–1.02) 0.44 (0.20–0.98) 0.0
Inadequate or unclear 11 1477 0.45 (0.29–0.69) 0.41 (0.29–0.60) 10.7
Sample size  
52200 patients 0 0   
<2200 patients 13 2028 0.46 (0.32–0.65) 0.42 (0.30–0.59) 0.0
B. Until 1995, before ISIS-414
Overall 15 4559 0.48 (0.34–0.67) 0.57 (0.47–0.70) 30.6
Concealment of allocation 0.64 0.036
Adequate 4 2531 0.50 (0.28–0.91) 0.67 (0.52–0.85) 50.0
Inadequate or unclear 11 2028 0.45 (0.29–0.69) 0.41 (0.29–0.60) 10.7
Sample size 0.094 0.002
52200 patients 1 2316 0.76 (0.59–0.99) 0.76 (0.59–0.99) 0.0
<2200 patients 14 2243 0.43 (0.31–0.60) 0.39 (0.29–0.54) 0.0
C. Until 1995, including ISIS-414
Overall 16 62 609 0.53 (0.38–0.75) 1.01 (0.95–1.06) 66.8
Concealment of allocation 0.25 <0.001
Adequate 5 60 581 0.69 (0.46–1.03) 1.03 (0.97–1.09) 77.3
Inadequate or unclear 11 2028 0.45 (0.29–0.69) 0.41 (0.29–0.60) 10.7
Sample size 0.007 <0.001
52200 patients 2 60 366 0.92 (0.67–1.26) 1.04 (0.98–1.10) 82.4
<2200 patients 14 2243 0.43 (0.31–0.60) 0.39 (0.29–0.54) 0.0
D. All trials14,24
Overall 24 72 920 0.65 (0.53–0.80) 0.98 (0.93–1.03) 65.8
Concealment of allocation 0.40 <0.001
Adequate 9 67 945 0.80 (0.65–0.98) 1.02 (0.97–1.07) 71.7
Inadequate or unclear 15 4795 0.56 (0.43–0.74) 0.58 (0.47–0.71) 7.6
Sample size 0.001 <0.001
52200 patients 4 69 758 0.89 (0.75–1.06) 1.01 (0.97–1.07) 83.0
<2200 patients 20 2982 0.42 (0.32–0.57) 0.39 (0.30–0.52) 0.0
Results from stratified analysis according to allocation concealment and sample size are presented using fixed- and random-effects
models including trials published until 1991 and before LIMIT-2; until 1995 and before ISIS-4, until 1995 including ISIS-4 and
up to 2004. P-values for interaction between treatment effect and trial characteristics were derived using meta-regression for
random-effects models and z-tests for fixed-effect models.
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random- and fixed-effects meta-analyses are discor-
dant. Here, the appropriately powered tests of funnel
plot asymmetry and tests of interaction between sample
size and treatment effect indicate that the inclusion of
trials of inadequate size leads to a severe distortion of
results.
Egger and Davey Smith concluded in 1995 that
‘results of meta-analyses that are exclusively based
on small trials should be distrusted - even if the
combined effect is statistically highly significant.
Several medium-sized trials of high quality seem
necessary to render results trustworthy.’5 These
conclusions still hold in 2009. If appropriately used
and interpreted, funnel plots with formal statistical
tests of asymmetry, stratified analyses accompanied
by tests of interaction and heterogeneity-adjusted trial
sequential analyses will all contribute to our under-
standing about when to consider a meta-analysis
conclusive.
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